Flexion Reports Year-End 2015 Financial Results
Mar 10, 2016 21:01 pm UTC| Business
Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta™, Flexion’s lead drug candidate (also known as FX006)Zilretta received Fast-Track designation by U.S. Food Drug...
Mar 10, 2016 21:00 pm UTC| Business
DENVER, March 10, 2016 -- Bonanza Creek Energy, Inc. (NYSE:BCEI) announces it has elected to draw down $209 million on its credit facility, and currently has an aggregate of $300 million of borrowings, including a $12...
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2015 Results
Mar 10, 2016 21:00 pm UTC| Business
NASHVILLE, Tenn., March 10, 2016 -- Surgery Partners, Inc.(NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the fourth quarter and full year...
Kratos Reports Fourth Quarter and Fiscal 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
Fourth Quarter Revenues of $177.5M Increase 9.8% Over Third Quarter Full Year Revenues of $657.1M Fourth Quarter Adjusted EBITDA of $13.4 Million SAN DIEGO, March 10, 2016 -- Kratos Defense Security Solutions,...
STRATA Skin Sciences Reports Fourth Quarter 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
Proforma XTRAC Recurring Revenue Growth of 16.1% in CY 2015 Achieved Positive Non-GAAP Adjusted EBIDTA for Second Consecutive Quarter HORSHAM, Pa., March 10, 2016 -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN)...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
EMERYVILLE, Calif., March 10, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and...
STRATA Skin Sciences, Inc. Announces FDA Approval of PMA Supplemental for MelaFind®
Mar 10, 2016 21:00 pm UTC| Business
Study including Classifier Score Data shows increased Sensitivity and Specificity FDA Post-Approval Study Termination provides cost savings Greater flexibility to explore strategic value of MelaFind System in Clinical...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood